Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
100 participants
OBSERVATIONAL
2020-01-01
2025-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Although induction chemotherapy results in remission in many older patients with AML, relapse is common and overall survival is poor. For patients not eligible for HSCT, maintenance therapies are needed to reduce the risk of relapse and prolong overall survival without causing undue adverse effects or compromising health-related quality of life. Oral azacitidine (ONUREG) has been approved by FDA on September, 2020, to treat adult patients with AML who achieved CR or CRi following intensive induction chemotherapy with or without consolidation and who are not able to complete intensive curative therapy (not candidate to HSCT).
The use of oral azacitidine maintenance is an integral part of clinical practice for AML patients who have achieved a first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) after intensive ""3+7"" induction chemotherapy and who are unable to complete intensive curative therapy.
But there are few data on its efficacy as a post-CPX-351 maintenance agent in patients with newly diagnosed t-AML or AML-MRC or de novo AML.THe aim of this study is to show the improvement of overall survival with use of oral Azacitidine as maintenance for patients with de novo AML including t-AML or AML-MRC who achieved complete remission or complete remission with incomplete blood count recovery after CPX-351. Long-term product safety is also being studied
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
NCT00822094
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
NCT00788892
CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia
NCT02286726
Investigator Initiated Trial of CPX-351 for Untreated Acute Myeloid Leukemia
NCT03335267
EAP of CPX-351 (VYXEOS) for Patients 60-75 Years of Age With Secondary AML
NCT02533115
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No intervention
Follow-up of disease
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* de novo AML including t-AML or AML-MRC according to WHO 2016
* Should have undergone induction therapy with CPX-351 with or without CPX-351 consolidation
* Patients in first line of treatment
* Should have achieved first CR/CRi/CRh status according to IWG criteria
* ECOG performance status of 0,1,2,3
Exclusion Criteria
* patients having achieved CR/CRi following an added therapy
* Patients alive at the start of the study who did not receive study information or who objected to the collection of data
64 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire de Nice
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU de Nice
Nice, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
CLUZEAU thomas
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
24Hemato01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.